Malignant Neoplasms of Testis (ICD-11: 2C80) - Complete Coding Guide

1. Introduction

Malignant neoplasms of the testis represent a heterogeneous group of tumors that originate from or secondarily affect testicular tissue. Although considered relatively rare when compared to other cancers, these neoplasms possess unique characteristics that make them clinically significant: they predominantly affect young men in their productive and reproductive years, present high cure rates when diagnosed early, and can have profound impact on fertility and quality of life.

ICD-11 code 2C80 encompasses all malignant testicular neoplasms, whether primary (originating in the testis itself) or metastatic (originating from other sites). This categorization includes the most common germ cell tumors, such as seminoma and embryonal carcinoma, as well as rarer neoplasms such as sarcomas, leukemias, and lymphomas that secondarily affect the testis.

The clinical importance of these neoplasms transcends their incidence. They represent the most common solid malignancy in men between 15 and 35 years of age, an age group generally healthy and economically active. Correct and timely diagnosis is crucial, as even in advanced stages, many of these tumors show excellent response to treatment, with cure rates exceeding 90% in localized cases.

Precise coding using code 2C80 is fundamental for epidemiological surveillance, resource planning in oncology, clinical research, and ensuring adequate access to specialized treatments. Coding errors can result in underreporting, difficulties in tracking outcomes, and administrative problems related to coverage of specific oncologic treatments.

2. Correct ICD-11 Code

Code: 2C80

Description: Malignant neoplasms of testis

Parent category: Malignant neoplasms of male genital organs

Official definition: Primary or metastatic malignant neoplasm affecting the testis. Representative examples include seminoma, embryonal carcinoma, sarcoma, leukemia, and lymphoma.

This code represents a comprehensive classification that encompasses all histological types of testicular malignancies. ICD-11 maintains a hierarchical structure where 2C80 functions as the main category, allowing additional specifications through subcategories when it is necessary to identify the specific histological type.

The official definition highlights two fundamental aspects: first, it includes both primary neoplasms (which originate in the testis) and metastatic neoplasms (which disseminate to the testis from other sites); second, it exemplifies the main histological types without limiting the application of the code to only these examples.

The positioning of this code within the category of malignant neoplasms of male genital organs facilitates navigation in the classification system and ensures that healthcare professionals can quickly locate the correct code when documenting urological oncological diagnoses. This systematic organization also aids in epidemiological analyses that compare different types of male genital cancers.

3. When to Use This Code

Code 2C80 should be applied in specific clinical situations where there is diagnostic confirmation of testicular malignancy. Below are detailed practical scenarios:

Scenario 1: Diagnosed Classic Seminoma A 32-year-old patient presents with painless enlargement of the left testis. Ultrasonography reveals a 3 cm solid intratesticular mass. Tumor markers show discrete elevation of beta-HCG, with normal alpha-fetoprotein. Radical inguinal orchiectomy is performed, and histopathological examination confirms classic seminoma. In this case, 2C80 is the appropriate code, as there is histological confirmation of primary malignant neoplasm of the testis.

Scenario 2: Mixed Germ Cell Tumor A 25-year-old patient with right testicular mass and significantly elevated tumor markers (AFP >1000 ng/mL). Following orchiectomy, the pathologist identifies components of embryonal carcinoma (60%), mature teratoma (30%), and seminoma (10%). Even though it is a mixed tumor, 2C80 is applicable as the primary code and may be supplemented with additional specifications regarding histological components.

Scenario 3: Primary Testicular Lymphoma A 68-year-old man presents with progressive bilateral testicular enlargement. Biopsy reveals primary diffuse large B-cell lymphoma of the testis. Although it is a hematologic neoplasm, when it primarily affects the testis, code 2C80 is appropriate, as the official definition explicitly includes lymphoma as an example of testicular malignant neoplasm.

Scenario 4: Testicular Metastasis from Prostatic Carcinoma A patient with a history of advanced prostatic adenocarcinoma develops a testicular nodule. Biopsy confirms metastasis of prostatic carcinoma in the testis. Code 2C80 is applicable because the definition encompasses metastatic neoplasms affecting the testis, although it is also necessary to code the primary prostatic neoplasm (2C82).

Scenario 5: Testicular Sarcoma A 16-year-old adolescent with rapidly growing testicular mass. Histopathological examination following orchiectomy identifies embryonal rhabdomyosarcoma originating in the testis. Despite being a rare mesenchymal tumor, when primary to the testis, 2C80 is the correct code, as sarcoma is listed among the representative examples.

Scenario 6: Yolk Sac Tumor in a Child A 2-year-old child with scrotal mass and extremely elevated AFP. Surgery and histology confirm yolk sac tumor (endodermal sinus tumor). This pediatric germ cell tumor is appropriately coded as 2C80, representing primary testicular malignant neoplasm.

4. When NOT to Use This Code

It is fundamental to recognize situations where code 2C80 is not appropriate, avoiding coding errors that may compromise medical records and epidemiological statistics.

Specific Mesenchymal Neoplasms: If the documentation clearly specifies a mesenchymal neoplasm with a more specific code available, this should be prioritized. For example, if there is a dedicated code for malignant mesenchymal neoplasms of the testis (1965082709), this should be used instead of the generic code 2C80 when applicable, according to coding guidelines that prioritize specificity.

Benign Testicular Lesions: Benign tumors such as Leydig cell adenoma, benign Sertoli cell tumor, or pure mature teratoma in children should not be coded as 2C80. These require codes from the benign neoplasm category, even when they require surgical removal.

Paratesticular Structure Neoplasms: Tumors originating in the epididymis, spermatic cord, or testicular tunics are not coded as 2C80. For example, a liposarcoma of the spermatic cord requires specific coding for neoplasms of the spermatic cord, not of the testis proper.

Scrotal Neoplasms: Carcinomas of scrotal skin, even when extensive, should be coded as 2C83 (malignant neoplasms of the scrotum), not as 2C80. Anatomical distinction is crucial: code 2C80 refers specifically to testicular parenchyma.

Unconfirmed Suspicion: When there is only clinical or radiological suspicion of testicular malignancy, without histopathological confirmation, 2C80 should not be used. In these cases, codes for symptoms or abnormal findings are more appropriate until there is definitive diagnostic confirmation.

Post-Treatment Complications: Sequelae or late complications of prior testicular cancer treatment (such as secondary infertility, hypogonadism, or psychological problems) should not be coded as 2C80, but rather with codes appropriate for the specific complications, and may reference personal history of testicular neoplasm.

5. Step-by-Step Coding Process

Step 1: Assess Diagnostic Criteria

The diagnostic confirmation of malignant testicular neoplasia requires multiple evaluation stages. Initially, physical examination identifies a mass or alteration in testicular consistency. Scrotal ultrasound with Doppler is the essential initial imaging examination, identifying solid intratesticular lesions that raise suspicion for malignancy.

Serum tumor markers are fundamental: alpha-fetoprotein (AFP), human chorionic gonadotropin beta fraction (beta-hCG), and lactate dehydrogenase (LDH). Significant elevations of these markers, especially AFP and beta-hCG, strengthen diagnostic suspicion and aid in probable histological classification.

Definitive confirmation occurs through histopathological examination of the surgical specimen obtained by radical inguinal orchiectomy. Percutaneous biopsy is contraindicated due to the risk of tumor dissemination. The histopathological report must specify the histological type, degree of differentiation, vascular invasion, tunica albuginea invasion, and surgical margins.

Imaging studies for staging (chest, abdomen, and pelvis computed tomography) are necessary before finalizing coding, as they identify metastatic disease that may influence complete diagnostic documentation.

Step 2: Verify Specifiers

After confirming that it is a malignant testicular neoplasia, it is necessary to document specific characteristics that may require additional coding or modifiers. The histological type must be clearly identified: seminoma, embryonal carcinoma, choriocarcinoma, yolk sac tumor, teratoma, or combinations thereof.

Clinical staging according to international classifications (such as TNM system) must be recorded, as it influences prognosis and treatment. Documenting whether the neoplasia is primary to the testis or represents metastasis from another primary site is essential.

Laterality must be specified (right, left, or bilateral), as well as characteristics such as invasion of adjacent structures, presence of intratubular germ cell neoplasia (precursor), and status of pre- and post-operative tumor markers.

For metastatic tumors in the testis, identifying the primary site is mandatory, as it requires dual coding: the primary cancer and the testicular metastatic location.

Step 3: Differentiate from Other Codes

2C81 - Malignant neoplasia of penis: The fundamental difference lies in anatomical location. While 2C80 refers to testicular parenchyma, 2C81 applies to tumors of the penile body, glans, or prepuce. Even when there is advanced local extension, the correct code is determined by the primary site of origin. A penile carcinoma that invades the scrotum is not coded as 2C80.

2C82 - Malignant neoplasia of prostate: This distinction is generally clear anatomically. However, in cases of testicular metastasis from prostatic carcinoma, both codes are necessary: 2C82 as the primary diagnosis and 2C80 as the metastatic location. Differentiation is based on histopathological examination that identifies the cellular origin.

2C83 - Malignant neoplasias of scrotum: The scrotum is the cutaneous pouch containing the testes, but not the testis itself. Squamous cell carcinomas of the scrotum (classically associated with occupational exposures) are coded as 2C83. The differentiation is anatomical: 2C83 for scrotal skin and wall; 2C80 for the internal testicular parenchyma.

Neoplasias of paratesticular structures: Tumors of the epididymis, spermatic cord, or testicular hydatid require specific codes for these structures, not 2C80. Histopathological examination and surgical description should clarify the structure of origin.

Step 4: Required Documentation

An adequate record to justify code 2C80 must include:

Mandatory checklist:

• Description of physical examination identifying mass or testicular alteration
• Result of scrotal ultrasound with lesion characteristics
• Values of tumor markers (AFP, beta-hCG, LDH) preoperatively
• Surgical report of orchiectomy specifying approach (inguinal)
• Complete histopathological report with histological type, grade, invasions
• Laterality clearly specified
• Clinical staging based on imaging studies
• If metastatic, identification of primary site

Recommended complementary documentation:

• Temporal evolution of symptoms
• Risk factors present (cryptorchidism, family history)
• Results of staging computed tomography
• Proposed therapeutic plan (surveillance, chemotherapy, radiotherapy)
• Post-operative values of tumor markers

This complete documentation ensures that coding is auditable, justifiable, and useful for continuity of care, in addition to allowing reliable epidemiological analyses.

6. Complete Practical Example

Clinical Case

Initial Presentation: A 28-year-old male patient seeks medical care reporting perception of a "lump" in the right testicle for approximately two months. Denies significant pain but reports sensation of heaviness in the scrotum. Does not present systemic symptoms such as fever, weight loss, or night sweats. Relevant past medical history includes right cryptorchidism surgically corrected at 3 years of age. Denies smoking or illicit substance use.

Evaluation Performed: On physical examination, a hardened, non-painful mass of approximately 3 cm is identified at the superior pole of the right testicle. The left testicle presents normal characteristics. No palpable inguinal lymphadenopathy.

Scrotal ultrasonography reveals a solid, hypoechoic, well-demarcated lesion measuring 2.8 x 2.5 cm in the right testicle, with increased vascularization on color Doppler. Left testicle without alterations.

Serum tumor markers: AFP = 145 ng/mL (reference value <10 ng/mL), beta-HCG = 8 mIU/mL (reference value <5 mIU/mL), LDH = 320 U/L (mildly elevated).

Computed tomography of chest, abdomen, and pelvis: left para-aortic retroperitoneal lymph node measuring 1.8 cm. Absence of pulmonary or visceral metastases.

Management and Diagnosis: Right radical inguinal orchiectomy was performed. Histopathological examination revealed: mixed germ cell tumor composed of embryonal carcinoma (70%) and immature teratoma (30%), measuring 3.2 cm in greatest dimension. Lymphovascular invasion present. Tunica albuginea invasion present. Surgical margins free. Intratubular germ cell neoplasia identified in adjacent testicular parenchyma.

Tumor markers 7 days after surgery: AFP = 42 ng/mL (declining), beta-HCG = 3 mIU/mL (normalized), indicating successful removal of primary tumor with expected marker half-life.

Final staging: Non-seminomatous germ cell tumor, stage IIA (T2 N1 M0 S1).

Diagnostic Reasoning: The combination of clinical, radiological, and laboratory findings establishes the diagnosis of testicular malignant neoplasm. The history of cryptorchidism is a known risk factor. Presentation as a painless testicular mass is classic. Elevation of AFP confirms non-seminomatous component. Histopathological confirmation defines the definitive diagnosis of mixed germ cell tumor, which is a primary malignant neoplasm of the testicle.

Step-by-Step Coding

Criteria Analysis:

1. Histopathological confirmation of malignant neoplasm: ✓ (embryonal carcinoma + immature teratoma)
2. Primary location in testicle: ✓ (confirmed by surgery and pathology)
3. Not a benign neoplasm: ✓ (malignant components clearly identified)
4. Not a paratesticular structure: ✓ (origin in testicular parenchyma)

Code Selected: 2C80

Complete Justification: Code 2C80 (Malignant neoplasms of testicle) is the correct code because:

• There is histopathological confirmation of primary malignant neoplasm of the testicle
• The tumor originated in the testicular parenchyma, not in adjacent structures
• The histological type (mixed germ cell tumor) is included in the representative examples of the official definition (embryonal carcinoma)
• There is no indication that it is a metastasis from another primary site
• The complete documentation unequivocally supports the diagnosis

Applicable Complementary Codes:

• Oncological staging code to document stage IIA
• Code for history of cryptorchidism as a risk factor
• Procedure code for radical orchiectomy
• Codes for adjuvant chemotherapy if indicated in the therapeutic plan

Additional Considerations: This case illustrates the importance of precise coding. The patient will require prolonged oncological follow-up, possibly adjuvant chemotherapy, and tumor marker monitoring. Correct coding ensures that these services are adequately authorized and that the patient is included in cancer registries for epidemiological surveillance.

7. Related Codes and Differentiation

Within the Same Category

2C81: Malignant neoplasm of penis

When to use 2C81: This code applies to malignant neoplasms originating from penile structures: penile body, glans, prepuce, or penile urethra. The most common histological type is squamous cell carcinoma, frequently associated with HPV infection or chronic inflammatory conditions such as lichen sclerosus.

Main difference versus 2C80: The distinction is purely anatomical. While 2C80 refers to intra-testicular testicular parenchyma, 2C81 refers to the penile organ. Even in advanced cases with extensive local invasion, the correct code is determined by the primary site of origin. A penile carcinoma that invades the scrotum remains coded as 2C81, not 2C80. Histology also characteristically differs: penile tumors are predominantly squamous cell carcinomas, while testicular tumors are typically germ cell tumors.

2C82: Malignant neoplasm of prostate

When to use 2C82: Applies to adenocarcinomas and other primary malignant neoplasms of the prostate gland. It is the most common male genital cancer in older men, typically diagnosed through elevated PSA and confirmed by transrectal or transperineal prostate biopsy.

Main difference versus 2C80: Differentiation is based on anatomical location and cell origin. Prostatic tumors originate from prostatic glandular epithelium, while testicular tumors originate from germ cells or testicular stroma. Typical age range also differs: prostate cancer is predominantly a disease of men over 60 years old, while testicular cancer primarily affects young men. Important: in cases of testicular metastasis from prostatic carcinoma, both codes are necessary: 2C82 as primary and 2C80 as metastatic location.

2C83: Malignant neoplasms of scrotum

When to use 2C83: This code is appropriate for neoplasms originating from the scrotal skin or wall, not from the testis itself. Historically, scrotal carcinomas have been associated with occupational exposures (such as contact with hydrocarbons) and are relatively rare.

Main difference versus 2C80: The distinction is anatomical: 2C83 for the scrotal sac (skin and wall tissues); 2C80 for testicular content. Clinically, scrotal tumors present as lesions or masses on scrotal skin, frequently ulcerated, while testicular tumors manifest as palpable masses within the testis. Histology also differs: scrotal tumors are typically cutaneous squamous cell carcinomas, while testicular tumors are predominantly germ cell tumors.

Differential Diagnoses

Orchitis and Epididymitis: Infectious inflammatory processes can mimic testicular neoplasms, causing testicular enlargement and discomfort. Differentiation is based on: acute onset (infection) versus insidious (tumor), presence of fever and systemic symptoms (more common in infection), ultrasonography showing diffuse enlargement with hypervascularization (infection) versus focal mass (tumor), and response to antibiotics (infection). Tumor markers are normal in infectious processes.

Hydrocele and Spermatocele: These are benign fluid collections that increase scrotal volume but do not represent solid testicular masses. Ultrasonography clearly differentiates: anechoic collections (fluid) versus solid intratesticular masses. They do not require coding as neoplasm.

Testicular Torsion: Urological emergency causing acute severe testicular pain. Differentiated by hyperacute presentation, severe pain, and Doppler ultrasonography showing absence of testicular blood flow (versus increased flow in tumors). Requires coding of acute condition, not neoplasm.

Varicocele: Varicose dilatation of the veins of the pampiniform plexus, causing scrotal heaviness sensation. Differentiated by characteristic physical examination ("bag of worms"), disappearance in recumbency, and ultrasonography showing dilated veins without testicular mass. It is a benign non-neoplastic condition.

8. Differences with ICD-10

Equivalent ICD-10 Code: In ICD-10, malignant neoplasms of the testis are coded as C62, with subdivisions: C62.0 (undescended testis), C62.1 (descended testis), and C62.9 (testis unspecified).

Main Changes in ICD-11: The transition to ICD-11 brings structural simplification. While ICD-10 differentiated descended versus undescended testes (reflecting cryptorchidism as a risk factor), ICD-11 unifies under code 2C80, eliminating this subdivision based on previous testicular location. The history of cryptorchidism can be documented separately as a risk factor, but does not determine a different code.

ICD-11 offers greater flexibility for specification of histological types through extensions and modifiers, allowing more detailed documentation when necessary, while maintaining a simpler and more universal primary code.

Practical Impact: This change simplifies coding, eliminating the need to determine whether the testis was previously cryptorchidic to choose between C62.0 and C62.1. All cases of malignant testicular neoplasm now use 2C80 as the base code, regardless of cryptorchidism history. This reduces coding errors and facilitates epidemiological analyses, although it requires an adaptation period for professionals accustomed to ICD-10 structure. Health information systems require updates to mappings and conversion tables to ensure continuity of historical records.

9. Frequently Asked Questions

1. How is testicular malignant neoplasia diagnosed?

Diagnosis begins with physical examination identifying a mass or testicular alteration. Scrotal ultrasonography is the initial imaging study, identifying solid intratesticular lesions. Serum tumor markers (AFP, beta-HCG, LDH) assist in classification and prognosis. Definitive confirmation occurs through histopathological examination of the surgical specimen obtained by radical inguinal orchiectomy. Percutaneous biopsy is contraindicated due to the risk of tumor dissemination. Staging studies (chest and abdominal computed tomography) are performed before definitive treatment to identify metastatic disease.

2. Is treatment available in public health systems?

Yes, treatment of testicular malignant neoplasias is generally available in public health systems in most countries, being considered a priority because it affects a young population and presents high cure rates. Treatment includes surgery (orchiectomy), platinum-based chemotherapy for advanced cases, and radiotherapy for seminomas. However, the specific availability of more modern protocols and access to specialized centers may vary depending on the region and local resources.

3. How long does treatment last?

Duration varies depending on stage and histological type. Localized seminoma cases may require only orchiectomy followed by active surveillance, without additional treatment. Cases requiring adjuvant chemotherapy typically receive 3-4 cycles over 9-12 weeks. Advanced metastatic disease may require 4 cycles of intensive chemotherapy, possible salvage surgery for residual masses, totaling 4-6 months of active treatment. Oncological follow-up extends for many years, with periodic consultations and examinations.

4. Can this code be used in medical certificates?

Yes, code 2C80 can and should be used in official medical documentation, including certificates when appropriate. However, considerations regarding patient privacy must be observed. In certificates for occupational purposes, one may opt for more generic descriptions such as "malignant neoplasia" without specifying the affected organ, according to patient preference and local regulations on medical confidentiality. For internal health system documentation, the complete code should always be recorded for adequate continuity of care.

5. Do testicular tumors always require testicular removal?

In the vast majority of cases, yes. Radical inguinal orchiectomy is both diagnostic and therapeutic, being the standard treatment. In very selected situations (synchronous bilateral tumor, single testis, very small tumors with normal markers), testis-sparing surgery may be considered, but it is exceptional and requires careful evaluation at specialized centers. Removal is necessary because most testicular tumors are malignant and orchiectomy offers excellent local control with low morbidity.

6. Do testicular neoplasias affect fertility?

Yes, they can affect fertility through multiple mechanisms. The tumor itself can compromise sperm production. Orchiectomy removes one testis, reducing sperm-producing tissue by half, although the remaining testis frequently compensates. Chemotherapy, especially intensive regimens, can cause temporary or permanent infertility. Therefore, semen cryopreservation before treatment is strongly recommended for patients wishing to preserve fertility. Many patients maintain adequate fertility even after treatment, but discussion about fertility preservation should occur before therapy begins.

7. What is the prognosis of testicular malignant neoplasias?

The prognosis is generally excellent, especially when diagnosed early. Localized tumors (stage I) present cure rates exceeding 95%. Even metastatic disease has good prognosis, with cure rates of 70-80% for advanced disease. Seminomas tend to have slightly better prognosis than non-seminomas. Adverse prognostic factors include very high elevation of tumor markers, multiple visceral metastases, and choriocarcinoma component. Prolonged follow-up is essential, as recurrences may occur, but even recurrences are frequently curable with salvage treatment.

8. Is follow-up necessary after treatment?

Yes, prolonged oncological follow-up is essential. The typical protocol includes periodic consultations with physical examination, tumor marker dosing, and imaging studies (computed tomography or radiography) at intervals that vary depending on initial stage and histological type. In the first two years, consultations are more frequent (every 2-3 months), then gradually spaced out. Follow-up extends for at least 5-10 years, as late recurrences, although rare, may occur. Beyond oncological surveillance, monitoring of late treatment effects (cardiovascular function, renal function, hypogonadism) is also important.

Conclusion

Appropriate coding of malignant testicular neoplasms using ICD-11 code 2C80 is fundamental to ensure accurate documentation, continuity of oncologic care, reliable epidemiological analyses, and appropriate access to therapeutic resources. This article provided detailed guidance on when to use this code, how to differentiate it from related codes, and how to properly document clinical cases.

Healthcare professionals should remember that histopathological confirmation is essential before applying code 2C80, and that complete documentation including histological type, staging, and specific tumor characteristics enriches the medical record and facilitates multidisciplinary management of these patients. The transition from ICD-10 to ICD-11 simplifies the coding structure, but requires familiarity with the new conventions and hierarchical organization.

External References

This article was prepared based on reliable scientific sources:

1. 🌍 WHO ICD-11 - Malignant neoplasms of testis
2. 🔬 PubMed Research on Malignant neoplasms of testis
3. 🌍 WHO Health Topics
4. 📊 Clinical Evidence: Malignant neoplasms of testis
5. 📋 Ministry of Health - Brazil
6. 📊 Cochrane Systematic Reviews

References verified on 2026-02-03